Prospective Clinical Investigation to Evaluate the Safety and Effectiveness of Juläine™ in Improving Gluteal Skin Laxity in Adults.

Inclusion Criteria: * Adults aged 18 to 55 years; * Body Mass Index (BMI) between 18.5 and 24.95 kg/m². * Skin laxity of the gluteal region defined as sagging and reduced tightness of the skin. * Women of childbearing potential must be willing to abide by the contraceptive requirements * Ability to understand the study and provide informed consent, attend follow-up visits, and follow post-injection instructions. Exclusion Criteria: * Pregnancy or breastfeeding, or planned pregnancy/lack of adequate contraception (through 8 weeks post-study); * Is planning to donate/bank or retrieve eggs (ova, oocytes) or donate sperm during the study or within 8-weeks of the end of participation of the clinical investigation. * Active infection, inflammation or lesions at or near the treatment site. * Acute infection at screening; * History of autoimmune disease; * Immune deficiencies; * History of hypertrophic scarring or keloid formation; * Previous surgical procedures involving the buttocks * Aesthetic procedure on the buttocks (including fillers, elevation wires, radiofrequency, ultrasound, cryotherapy, fat injection, neurotoxin, laser or light treatment, or chemical peel) within 6 months prior to randomization. * Hemorrhagic disease or ongoing use of antiplatelets/anticoagulant therapy. * Treatment with chemotherapy, immunosuppressive agents, systemic corticosteroids within 3 months before treatment (inhaled or ophthalmic corticosteroids are allowed). * Use of hormonal replacement the…